Mark W. Linder

2.8k total citations
64 papers, 2.0k citations indexed

About

Mark W. Linder is a scholar working on Pharmacology, Molecular Biology and Cancer Research. According to data from OpenAlex, Mark W. Linder has authored 64 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmacology, 21 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Mark W. Linder's work include Pharmacogenetics and Drug Metabolism (23 papers), Cancer Genomics and Diagnostics (9 papers) and Hormonal Regulation and Hypertension (9 papers). Mark W. Linder is often cited by papers focused on Pharmacogenetics and Drug Metabolism (23 papers), Cancer Genomics and Diagnostics (9 papers) and Hormonal Regulation and Hypertension (9 papers). Mark W. Linder collaborates with scholars based in United States, Germany and India. Mark W. Linder's co-authors include Roland Valdes, Russell A. Prough, R Valdes, Kristen K. Reynolds, Lori Millner, P E Keck, Nancy Johnson, Bonny L. Bukaveckas, Beate Herpertz‐Dahlmann and Yusheng Zhu and has published in prestigious journals such as Journal of Biological Chemistry, The FASEB Journal and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Mark W. Linder

64 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Linder United States 24 902 394 312 300 268 64 2.0k
Pedro Dorado Spain 26 1.3k 1.4× 255 0.6× 193 0.6× 360 1.2× 464 1.7× 83 1.9k
Toyoko Hiroi Japan 32 1.2k 1.3× 825 2.1× 228 0.7× 208 0.7× 565 2.1× 65 2.7k
Maria Gabriella Scordo Italy 25 1.0k 1.1× 219 0.6× 233 0.7× 914 3.0× 308 1.1× 32 2.1k
James A. Eckstein United States 17 560 0.6× 618 1.6× 145 0.5× 144 0.5× 321 1.2× 25 1.8k
Sarah C. Sim Sweden 20 1.4k 1.5× 496 1.3× 196 0.6× 152 0.5× 639 2.4× 24 2.1k
J. Brockmöller Germany 7 778 0.9× 223 0.6× 109 0.3× 256 0.9× 230 0.9× 9 1.1k
Julio Benítez Spain 27 767 0.9× 464 1.2× 78 0.3× 269 0.9× 399 1.5× 52 1.9k
Juan Antonio Carrillo Spain 24 831 0.9× 383 1.0× 76 0.2× 376 1.3× 376 1.4× 54 2.0k
Lisa L. von Moltke United States 19 1.2k 1.3× 265 0.7× 128 0.4× 263 0.9× 596 2.2× 22 2.0k
Mike Ufer Switzerland 25 381 0.4× 273 0.7× 132 0.4× 172 0.6× 331 1.2× 67 1.9k

Countries citing papers authored by Mark W. Linder

Since Specialization
Citations

This map shows the geographic impact of Mark W. Linder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Linder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Linder more than expected).

Fields of papers citing papers by Mark W. Linder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Linder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Linder. The network helps show where Mark W. Linder may publish in the future.

Co-authorship network of co-authors of Mark W. Linder

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Linder. A scholar is included among the top collaborators of Mark W. Linder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Linder. Mark W. Linder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Egger, Michael E., et al.. (2024). Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment. Translational Oncology. 42. 101883–101883. 9 indexed citations
2.
Miller, Hunter A., et al.. (2024). The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden. Journal of Molecular Diagnostics. 26(11). 952–961. 4 indexed citations
3.
Linder, Mark W., Jim F. Huggett, Katarina Baluchova, et al.. (2023). Results from an IFCC global survey on laboratory practices for the analysis of circulating tumor DNA. Clinica Chimica Acta. 547. 117398–117398. 5 indexed citations
4.
Linder, Mark W., et al.. (2021). Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma. Molecular Diagnosis & Therapy. 25(3). 361–371. 4 indexed citations
5.
Killeen, Matthew J., et al.. (2013). NF-κβ signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities. Drug Discovery Today. 19(4). 373–378. 84 indexed citations
6.
Pendleton, Robert C., Gwendolyn A. McMillin, Kristen K. Reynolds, et al.. (2012). Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thrombosis and Haemostasis. 108(9). 561–569. 34 indexed citations
7.
Schimmelmann, Benno G., Susann Friedel, Astrid Dempfle, et al.. (2007). No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) in ADHD. Journal of Neural Transmission. 114(4). 523–526. 25 indexed citations
8.
Heiser, Philip, Astrid Dempfle, Susann Friedel, et al.. (2006). Family-based association study of serotonergic candidate genes and attention-deficit/hyperactivity disorder in a German sample. Journal of Neural Transmission. 114(4). 513–521. 32 indexed citations
9.
Walitza, Susanne, Tobias Renner, Astrid Dempfle, et al.. (2005). Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Molecular Psychiatry. 10(12). 1126–1132. 134 indexed citations
10.
Voora, Deepak, Charles Eby, Mark W. Linder, et al.. (2005). Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis. 93(4). 700–705. 154 indexed citations
11.
Hebebrand, Johannes, Astrid Dempfle, Kathrin Saar, et al.. (2005). A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. Molecular Psychiatry. 11(2). 196–205. 89 indexed citations
12.
Friedel, Susann, Frank Geller, Astrid Dempfle, et al.. (2004). Mutation screen of the brain derived neurotrophic factor gene (BDNF): Identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention‐deficit/hyperactivity disorder. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 132B(1). 96–99. 123 indexed citations
13.
Bukaveckas, Bonny L., Roland Valdes, & Mark W. Linder. (2004). Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. Journal of Cardiothoracic and Vascular Anesthesia. 18(3). 353–365. 5 indexed citations
14.
Linder, Mark W., et al.. (2002). Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms. Journal of Thrombosis and Thrombolysis. 14(3). 227–232. 76 indexed citations
15.
Linder, Mark W. & Roland Valdes. (2001). Genetic Mechanisms for Variability in Drug Response and Toxicity. Journal of Analytical Toxicology. 25(5). 405–413. 18 indexed citations
16.
Weintraub, Daniel & Mark W. Linder. (2000). Amphetamine positive toxicology screen secondary to bupropion. Depression and Anxiety. 12(1). 53–54. 23 indexed citations
17.
Linder, Mark W., et al.. (2000). Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clinica Chimica Acta. 295(1-2). 179–185. 11 indexed citations
18.
Linder, Mark W., et al.. (1999). Pharmacogenetics in the practice of laboratory medicine. Molecular Diagnosis. 4(4). 365–379. 27 indexed citations
19.
Smith, Jeanne A., Mark W. Linder, D. Fernandez, & Russell A. Prough. (1991). Differential regulation of hepatic enzymes by polycyclic aromatic hydrocarbons and glucocorticoids. 1 indexed citations
20.
Prough, Russell A., et al.. (1989). Modulation of the Polycycuc Aromatic Hydrocarbon-Dependent Induction of Cytochrome P450ia1 By Glucocorticoids. Drug Metabolism Reviews. 20(2-4). 585–599. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pedro Dorado Breakdown of academic impact, for papers by Toyoko Hiroi Breakdown of academic impact, for papers by Maria Gabriella Scordo Breakdown of academic impact, for papers by James A. Eckstein Breakdown of academic impact, for papers by Sarah C. Sim Breakdown of academic impact, for papers by J. Brockmöller Breakdown of academic impact, for papers by Julio Benítez Breakdown of academic impact, for papers by Juan Antonio Carrillo Breakdown of academic impact, for papers by Lisa L. von Moltke Breakdown of academic impact, for papers by Mike Ufer
Rankless by CCL
2026